-
Stamulumab (MYO-029) is an
experimental myostatin inhibiting drug
developed by
Wyeth Pharmaceuticals for the
treatment of
muscular dystrophy (MD). Stamulumab...
-
disable myostatin,
including apitegromab, domagrozumab, landogrozumab, and
stamulumab.
Another form of
myostatin inhibition is gene therapy.
Another monoclonal...
- the market. An
antibody genetically engineered to
neutralize myostatin,
stamulumab,
which was
under development by
pharmaceutical company Wyeth, is no longer...
-
Gremlin (Drm) LTBP1
Noggin TGIF
Thrombospondin 1 (THBS1)
Tomoregulin 1 Antibodies:
Stamulumab (against myostatin) TRC105 (against endoglin) Others: Endoglin...
-
Gremlin (Drm) LTBP1
Noggin TGIF
Thrombospondin 1 (THBS1)
Tomoregulin 1 Antibodies:
Stamulumab (against myostatin) TRC105 (against endoglin) Others: Endoglin...
- Germany: John
Wiley & Sons. p. 2131. ISBN 978-3-527-32937-3.
Entry on
Stamulumab. at: Römpp Online.
Georg Thieme Verlag,
retrieved 2021-11-17. AGN (1931)...
- SSKI
stacofylline (INN)
Stadol Stahist Stalevo 100
stallimycin (INN)
stamulumab (INN, USAN) Stan-Gard
Stanozide stanozolol (INN)
Staphcillin Starlix Starnoc...
-
Gremlin (Drm) LTBP1
Noggin TGIF
Thrombospondin 1 (THBS1)
Tomoregulin 1 Antibodies:
Stamulumab (against myostatin) TRC105 (against endoglin) Others: Endoglin...
-
Gremlin (Drm) LTBP1
Noggin TGIF
Thrombospondin 1 (THBS1)
Tomoregulin 1 Antibodies:
Stamulumab (against myostatin) TRC105 (against endoglin) Others: Endoglin...
- that
calcium dysregulation pla**** a part in
muscle cell death. MYO-029 (
stamulumab), an
antibody that
inhibits myostatin, was
developed to
promote muscle...
